Zhang Jing, Fang Wenting, Liu Hanchen, Li Ran, Zhu Zhibao, Wu Xin, Yao Shaobo, Fu Ying, Li Rui, Chen Wanjin, Ye Qinyong, Liu Qiang, Chen Xiaochun
Department of Neurology, Fujian Medical University Union Hospital, Fujian Key Laboratory of Molecular Neurology and Institute of Neuroscience, Fujian Medical University, Fuzhou, China.
Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
Signal Transduct Target Ther. 2025 Sep 18;10(1):312. doi: 10.1038/s41392-025-02419-0.
Bone marrow is a major source of hematogenous cells that orchestrate brain immunity. However, alterations in the bone marrow hematopoietic system in patients with Alzheimer's disease (AD) and their potential impacts on neuroinflammation and cerebral β-amyloid (Aβ) pathology remain unknown. Here, we report that Aβ accumulates within the bone marrow of patients with AD and is particularly concentrated in the central nervous system-surrounding bones. In 5 × FAD and APP/PS1 mice, two classic mouse AD models, Aβ accumulates within the skull bone marrow prior to substantial cerebral Aβ deposits. Flow cytometry and cell tracking analyses demonstrated that these AD mice exhibit enhanced bone marrow hematopoiesis in B lymphoid lineages, specifically an increase in age-associated B cells (ABCs), accompanied by heightened output of these cells into the brain parenchyma. Furthermore, intracranial Aβ injection into IL-6 knockout mice revealed that Aβ promotes B lymphocyte generation, particularly ABCs, via IL-6 signaling. Single-cell sequencing analysis following intracerebroventricular ABCs injection, combined with in vitro microglial culture studies, demonstrated that bone marrow-derived ABCs directly augment microglial reactivity, ultimately exacerbating Aβ neuropathology and cognitive deficits in AD models. Notably, blockade of IL-6R restricts B-cell activity and ABCs in the bone marrow, delays cerebral Aβ pathology and improves cognition. Our findings reveal the potential involvement of bone marrow-derived B cells in the early cerebral amyloid pathology in two mouse AD models and suggest that these B cells may serve as potential therapeutic candidates for patients with AD.
骨髓是协调脑免疫的造血细胞的主要来源。然而,阿尔茨海默病(AD)患者骨髓造血系统的改变及其对神经炎症和脑β-淀粉样蛋白(Aβ)病理的潜在影响仍不清楚。在此,我们报告Aβ在AD患者的骨髓中积累,并且特别集中在中枢神经系统周围的骨骼中。在两种经典的小鼠AD模型5×FAD和APP/PS1小鼠中,在大量脑Aβ沉积之前,Aβ在颅骨骨髓中积累。流式细胞术和细胞追踪分析表明,这些AD小鼠在B淋巴细胞谱系中表现出增强的骨髓造血,特别是年龄相关B细胞(ABCs)增加,同时这些细胞向脑实质的输出增加。此外,向IL-6基因敲除小鼠脑内注射Aβ显示,Aβ通过IL-6信号通路促进B淋巴细胞生成,特别是ABCs。脑室内注射ABCs后的单细胞测序分析,结合体外小胶质细胞培养研究,表明骨髓来源的ABCs直接增强小胶质细胞反应性,最终加剧AD模型中的Aβ神经病理学和认知缺陷。值得注意的是,阻断IL-6R可限制骨髓中的B细胞活性和ABCs,延缓脑Aβ病理进程并改善认知。我们的研究结果揭示了骨髓来源的B细胞在两种小鼠AD模型早期脑淀粉样病理中的潜在作用,并表明这些B细胞可能成为AD患者潜在的治疗靶点。